Suven gets US product patent

The US Patent office has granted a product patent (US 7,297,711) to Suven Life Sciences, a Hyderabad-based pharmaceutical company. This is Suven's first product patent in the US.

The patent grant includes the class of selective serotonin receptor affinity compounds discovered by Suven and being developed as therapeutic agents.

According to the patent disclosure, the compounds are useful in the treatment of neuro-degenerative disorders such as Alzheimer's, Parkinson, Schizophrenia and Huntington's.

The market for such diseases in the US is estimated at $18 billion, a company release said.

Suven has so far filed 29 product patent applications across 145 countries. Of these, five patents have been granted so far.

Several other patent applications from Suven Discovery Research, that are in the pipeline, have completed the administrative and technical diligence in major countries and would be granted shortly, the company said.

Suven's shares closed at Rs 55.55, up by 19.21 per cent, on BSE today.